LncRNA TUG1 alleviates sepsis-induced acute lung injury by targeting miR-34b-5p/GAB1

Sepsis-induced acute lung injury (ALI) is a clinical syndrome characterized by the injury of alveolar epithelium and pulmonary endothelial cells. This study aimed to investigate the regulation of long noncoding RNA (lncRNA) taurine up-regulated gene 1 (TUG1) in a murine ALI model and in primary muri...

Full description

Saved in:
Bibliographic Details
Published inBMC pulmonary medicine Vol. 20; no. 1; pp. 49 - 12
Main Authors Qiu, Nan, Xu, Xinmei, He, Yingying
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 22.02.2020
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Sepsis-induced acute lung injury (ALI) is a clinical syndrome characterized by the injury of alveolar epithelium and pulmonary endothelial cells. This study aimed to investigate the regulation of long noncoding RNA (lncRNA) taurine up-regulated gene 1 (TUG1) in a murine ALI model and in primary murine pulmonary microvascular endothelial cells (PMVECs) stimulated with lipopolysaccharide (LPS). Adult C57BL/6 mice were intravenously injected with or without TUG1-expressiong adenoviral vector or control vector 1 week before the establishment of ALI model. PMVECs were transfected with TUG1-expressiong or control vectors followed by LPS stimulation. MiR-34b-5p was confirmed as a target of TUG1 using dual-luciferase reporter assay. GRB2 associated binding protein 1 (GAB1) was confirmed as a downstream target of miR-34b-5p using the same method. In the rescue experiment, PMVECs were co-transfected with TUG1-expressing vector and miR-34b-5p mimics (or control mimics) 24 h before LPS treatment. ALI mice showed reduced levels of TUG1, pulmonary injury, and induced apoptosis and inflammation compared to the control group. The overexpression of TUG1 in ALI mice ameliorated sepsis-induced pulmonary injury, apoptosis and inflammation. TUG1 also showed protective effect in LPS-treated PMVECs. The expression of MiR-34b-5p was negatively correlated with the level of TUG1. TUG1-supressed apoptosis and inflammation in LPS-stimulated PMVECs were restored by miR-34b-5p overexpression. GAB1 was inversely regulated by miR-34b-5p but was positively correlated with TUG1 expression. TUG1 alleviated sepsis-induced inflammation and apoptosis via targeting miR-34b-5p and GAB1. These findings suggested that TUG1 might be served as a therapeutic potential for the treatment of sepsis-induced ALI.
AbstractList Sepsis-induced acute lung injury (ALI) is a clinical syndrome characterized by the injury of alveolar epithelium and pulmonary endothelial cells. This study aimed to investigate the regulation of long noncoding RNA (lncRNA) taurine up-regulated gene 1 (TUG1) in a murine ALI model and in primary murine pulmonary microvascular endothelial cells (PMVECs) stimulated with lipopolysaccharide (LPS). Adult C57BL/6 mice were intravenously injected with or without TUG1-expressiong adenoviral vector or control vector 1 week before the establishment of ALI model. PMVECs were transfected with TUG1-expressiong or control vectors followed by LPS stimulation. MiR-34b-5p was confirmed as a target of TUG1 using dual-luciferase reporter assay. GRB2 associated binding protein 1 (GAB1) was confirmed as a downstream target of miR-34b-5p using the same method. In the rescue experiment, PMVECs were co-transfected with TUG1-expressing vector and miR-34b-5p mimics (or control mimics) 24 h before LPS treatment. ALI mice showed reduced levels of TUG1, pulmonary injury, and induced apoptosis and inflammation compared to the control group. The overexpression of TUG1 in ALI mice ameliorated sepsis-induced pulmonary injury, apoptosis and inflammation. TUG1 also showed protective effect in LPS-treated PMVECs. The expression of MiR-34b-5p was negatively correlated with the level of TUG1. TUG1-supressed apoptosis and inflammation in LPS-stimulated PMVECs were restored by miR-34b-5p overexpression. GAB1 was inversely regulated by miR-34b-5p but was positively correlated with TUG1 expression. TUG1 alleviated sepsis-induced inflammation and apoptosis via targeting miR-34b-5p and GAB1. These findings suggested that TUG1 might be served as a therapeutic potential for the treatment of sepsis-induced ALI.
Background Sepsis-induced acute lung injury (ALI) is a clinical syndrome characterized by the injury of alveolar epithelium and pulmonary endothelial cells. This study aimed to investigate the regulation of long noncoding RNA (lncRNA) taurine up-regulated gene 1 (TUG1) in a murine ALI model and in primary murine pulmonary microvascular endothelial cells (PMVECs) stimulated with lipopolysaccharide (LPS). Methods Adult C57BL/6 mice were intravenously injected with or without TUG1-expressiong adenoviral vector or control vector 1 week before the establishment of ALI model. PMVECs were transfected with TUG1-expressiong or control vectors followed by LPS stimulation. MiR-34b-5p was confirmed as a target of TUG1 using dual-luciferase reporter assay. GRB2 associated binding protein 1 (GAB1) was confirmed as a downstream target of miR-34b-5p using the same method. In the rescue experiment, PMVECs were co-transfected with TUG1-expressing vector and miR-34b-5p mimics (or control mimics) 24 h before LPS treatment. Results ALI mice showed reduced levels of TUG1, pulmonary injury, and induced apoptosis and inflammation compared to the control group. The overexpression of TUG1 in ALI mice ameliorated sepsis-induced pulmonary injury, apoptosis and inflammation. TUG1 also showed protective effect in LPS-treated PMVECs. The expression of MiR-34b-5p was negatively correlated with the level of TUG1. TUG1-supressed apoptosis and inflammation in LPS-stimulated PMVECs were restored by miR-34b-5p overexpression. GAB1 was inversely regulated by miR-34b-5p but was positively correlated with TUG1 expression. Conclusion TUG1 alleviated sepsis-induced inflammation and apoptosis via targeting miR-34b-5p and GAB1. These findings suggested that TUG1 might be served as a therapeutic potential for the treatment of sepsis-induced ALI.
Abstract Background Sepsis-induced acute lung injury (ALI) is a clinical syndrome characterized by the injury of alveolar epithelium and pulmonary endothelial cells. This study aimed to investigate the regulation of long noncoding RNA (lncRNA) taurine up-regulated gene 1 (TUG1) in a murine ALI model and in primary murine pulmonary microvascular endothelial cells (PMVECs) stimulated with lipopolysaccharide (LPS). Methods Adult C57BL/6 mice were intravenously injected with or without TUG1-expressiong adenoviral vector or control vector 1 week before the establishment of ALI model. PMVECs were transfected with TUG1-expressiong or control vectors followed by LPS stimulation. MiR-34b-5p was confirmed as a target of TUG1 using dual-luciferase reporter assay. GRB2 associated binding protein 1 (GAB1) was confirmed as a downstream target of miR-34b-5p using the same method. In the rescue experiment, PMVECs were co-transfected with TUG1-expressing vector and miR-34b-5p mimics (or control mimics) 24 h before LPS treatment. Results ALI mice showed reduced levels of TUG1, pulmonary injury, and induced apoptosis and inflammation compared to the control group. The overexpression of TUG1 in ALI mice ameliorated sepsis-induced pulmonary injury, apoptosis and inflammation. TUG1 also showed protective effect in LPS-treated PMVECs. The expression of MiR-34b-5p was negatively correlated with the level of TUG1. TUG1-supressed apoptosis and inflammation in LPS-stimulated PMVECs were restored by miR-34b-5p overexpression. GAB1 was inversely regulated by miR-34b-5p but was positively correlated with TUG1 expression. Conclusion TUG1 alleviated sepsis-induced inflammation and apoptosis via targeting miR-34b-5p and GAB1. These findings suggested that TUG1 might be served as a therapeutic potential for the treatment of sepsis-induced ALI.
Background Sepsis-induced acute lung injury (ALI) is a clinical syndrome characterized by the injury of alveolar epithelium and pulmonary endothelial cells. This study aimed to investigate the regulation of long noncoding RNA (lncRNA) taurine up-regulated gene 1 (TUG1) in a murine ALI model and in primary murine pulmonary microvascular endothelial cells (PMVECs) stimulated with lipopolysaccharide (LPS). Methods Adult C57BL/6 mice were intravenously injected with or without TUG1-expressiong adenoviral vector or control vector 1 week before the establishment of ALI model. PMVECs were transfected with TUG1-expressiong or control vectors followed by LPS stimulation. MiR-34b-5p was confirmed as a target of TUG1 using dual-luciferase reporter assay. GRB2 associated binding protein 1 (GAB1) was confirmed as a downstream target of miR-34b-5p using the same method. In the rescue experiment, PMVECs were co-transfected with TUG1-expressing vector and miR-34b-5p mimics (or control mimics) 24 h before LPS treatment. Results ALI mice showed reduced levels of TUG1, pulmonary injury, and induced apoptosis and inflammation compared to the control group. The overexpression of TUG1 in ALI mice ameliorated sepsis-induced pulmonary injury, apoptosis and inflammation. TUG1 also showed protective effect in LPS-treated PMVECs. The expression of MiR-34b-5p was negatively correlated with the level of TUG1. TUG1-supressed apoptosis and inflammation in LPS-stimulated PMVECs were restored by miR-34b-5p overexpression. GAB1 was inversely regulated by miR-34b-5p but was positively correlated with TUG1 expression. Conclusion TUG1 alleviated sepsis-induced inflammation and apoptosis via targeting miR-34b-5p and GAB1. These findings suggested that TUG1 might be served as a therapeutic potential for the treatment of sepsis-induced ALI. Keywords: Acute lung injury, Apoptosis, miRNA, GAB1, Sepsis, TUG1, Inflammation
Sepsis-induced acute lung injury (ALI) is a clinical syndrome characterized by the injury of alveolar epithelium and pulmonary endothelial cells. This study aimed to investigate the regulation of long noncoding RNA (lncRNA) taurine up-regulated gene 1 (TUG1) in a murine ALI model and in primary murine pulmonary microvascular endothelial cells (PMVECs) stimulated with lipopolysaccharide (LPS).BACKGROUNDSepsis-induced acute lung injury (ALI) is a clinical syndrome characterized by the injury of alveolar epithelium and pulmonary endothelial cells. This study aimed to investigate the regulation of long noncoding RNA (lncRNA) taurine up-regulated gene 1 (TUG1) in a murine ALI model and in primary murine pulmonary microvascular endothelial cells (PMVECs) stimulated with lipopolysaccharide (LPS).Adult C57BL/6 mice were intravenously injected with or without TUG1-expressiong adenoviral vector or control vector 1 week before the establishment of ALI model. PMVECs were transfected with TUG1-expressiong or control vectors followed by LPS stimulation. MiR-34b-5p was confirmed as a target of TUG1 using dual-luciferase reporter assay. GRB2 associated binding protein 1 (GAB1) was confirmed as a downstream target of miR-34b-5p using the same method. In the rescue experiment, PMVECs were co-transfected with TUG1-expressing vector and miR-34b-5p mimics (or control mimics) 24 h before LPS treatment.METHODSAdult C57BL/6 mice were intravenously injected with or without TUG1-expressiong adenoviral vector or control vector 1 week before the establishment of ALI model. PMVECs were transfected with TUG1-expressiong or control vectors followed by LPS stimulation. MiR-34b-5p was confirmed as a target of TUG1 using dual-luciferase reporter assay. GRB2 associated binding protein 1 (GAB1) was confirmed as a downstream target of miR-34b-5p using the same method. In the rescue experiment, PMVECs were co-transfected with TUG1-expressing vector and miR-34b-5p mimics (or control mimics) 24 h before LPS treatment.ALI mice showed reduced levels of TUG1, pulmonary injury, and induced apoptosis and inflammation compared to the control group. The overexpression of TUG1 in ALI mice ameliorated sepsis-induced pulmonary injury, apoptosis and inflammation. TUG1 also showed protective effect in LPS-treated PMVECs. The expression of MiR-34b-5p was negatively correlated with the level of TUG1. TUG1-supressed apoptosis and inflammation in LPS-stimulated PMVECs were restored by miR-34b-5p overexpression. GAB1 was inversely regulated by miR-34b-5p but was positively correlated with TUG1 expression.RESULTSALI mice showed reduced levels of TUG1, pulmonary injury, and induced apoptosis and inflammation compared to the control group. The overexpression of TUG1 in ALI mice ameliorated sepsis-induced pulmonary injury, apoptosis and inflammation. TUG1 also showed protective effect in LPS-treated PMVECs. The expression of MiR-34b-5p was negatively correlated with the level of TUG1. TUG1-supressed apoptosis and inflammation in LPS-stimulated PMVECs were restored by miR-34b-5p overexpression. GAB1 was inversely regulated by miR-34b-5p but was positively correlated with TUG1 expression.TUG1 alleviated sepsis-induced inflammation and apoptosis via targeting miR-34b-5p and GAB1. These findings suggested that TUG1 might be served as a therapeutic potential for the treatment of sepsis-induced ALI.CONCLUSIONTUG1 alleviated sepsis-induced inflammation and apoptosis via targeting miR-34b-5p and GAB1. These findings suggested that TUG1 might be served as a therapeutic potential for the treatment of sepsis-induced ALI.
Sepsis-induced acute lung injury (ALI) is a clinical syndrome characterized by the injury of alveolar epithelium and pulmonary endothelial cells. This study aimed to investigate the regulation of long noncoding RNA (lncRNA) taurine up-regulated gene 1 (TUG1) in a murine ALI model and in primary murine pulmonary microvascular endothelial cells (PMVECs) stimulated with lipopolysaccharide (LPS). Adult C57BL/6 mice were intravenously injected with or without TUG1-expressiong adenoviral vector or control vector 1 week before the establishment of ALI model. PMVECs were transfected with TUG1-expressiong or control vectors followed by LPS stimulation. MiR-34b-5p was confirmed as a target of TUG1 using dual-luciferase reporter assay. GRB2 associated binding protein 1 (GAB1) was confirmed as a downstream target of miR-34b-5p using the same method. In the rescue experiment, PMVECs were co-transfected with TUG1-expressing vector and miR-34b-5p mimics (or control mimics) 24 h before LPS treatment. ALI mice showed reduced levels of TUG1, pulmonary injury, and induced apoptosis and inflammation compared to the control group. The overexpression of TUG1 in ALI mice ameliorated sepsis-induced pulmonary injury, apoptosis and inflammation. TUG1 also showed protective effect in LPS-treated PMVECs. The expression of MiR-34b-5p was negatively correlated with the level of TUG1. TUG1-supressed apoptosis and inflammation in LPS-stimulated PMVECs were restored by miR-34b-5p overexpression. GAB1 was inversely regulated by miR-34b-5p but was positively correlated with TUG1 expression. TUG1 alleviated sepsis-induced inflammation and apoptosis via targeting miR-34b-5p and GAB1. These findings suggested that TUG1 might be served as a therapeutic potential for the treatment of sepsis-induced ALI.
ArticleNumber 49
Audience Academic
Author He, Yingying
Qiu, Nan
Xu, Xinmei
Author_xml – sequence: 1
  givenname: Nan
  orcidid: 0000-0002-5435-3296
  surname: Qiu
  fullname: Qiu, Nan
– sequence: 2
  givenname: Xinmei
  surname: Xu
  fullname: Xu, Xinmei
– sequence: 3
  givenname: Yingying
  surname: He
  fullname: He, Yingying
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32087725$$D View this record in MEDLINE/PubMed
BookMark eNp1kl9rFDEUxYNUbLv6AXyRAV98mTY3ySSZF2EtuhYWhbJ9Dpn8WbPMJutkprDf3qzbaluUPCTcnPu7OeGco5OYokPoLeALAMkvMxDZ4hoTXAOWrKYv0BkwATVhnJ88Op-i85w3GIOQDX2FTinBUgjSnKHVMpqbb_NqdbuASve9uwt6dLnKbpdDrkO0k3G20mYaXdVPcV2FuJmGfdXtq1EPazeGUtuGm5qyrm52l4v5J3iNXnrdZ_fmfp-h2y-fV1df6-X3xfXVfFkbTvhYM2IZ5lawjmkpJBjwjQQwhLG2BSukwcISyb135d3eWe1920oH1jEpjKAzdH3k2qQ3ajeErR72KumgfhfSsFZ6GIPpnaKUcqaBYK4tKwO6zmCDO2ioNNQzU1gfj6zd1G2dNS6Og-6fQJ_exPBDrdOdEphyArwAPtwDhvRzcnlU25CN63sdXZqyIpRTXIzJg_T9M-kmTUMsX1VUogVBKBZ_VWtdDIToU5lrDlA158BZiUADRXXxD1VZ1m2DKXnxodSfNLx7bPSPw4dMFIE4CsyQch6cVyaMegzp4Dv0CrA6pE8d06dK-tQhfeWLZwiedT7A_9_zCzbs14g
CitedBy_id crossref_primary_10_1186_s40246_021_00349_w
crossref_primary_10_1536_ihj_23_155
crossref_primary_10_1186_s12950_021_00296_2
crossref_primary_10_1007_s10528_023_10465_y
crossref_primary_10_1186_s12935_022_02797_3
crossref_primary_10_2147_JIR_S315985
crossref_primary_10_1016_j_prp_2022_154142
crossref_primary_10_1007_s10753_022_01735_9
crossref_primary_10_1016_j_gendis_2023_06_014
crossref_primary_10_1016_j_meegid_2021_104860
crossref_primary_10_3390_ijms23169354
crossref_primary_10_1080_08916934_2023_2259131
crossref_primary_10_1186_s13287_022_02921_0
crossref_primary_10_1159_000522231
crossref_primary_10_5114_aoms_175468
crossref_primary_10_1021_acsinfecdis_4c00052
crossref_primary_10_1080_0886022X_2021_1871922
crossref_primary_10_1155_2021_6278526
crossref_primary_10_3389_fimmu_2021_798713
crossref_primary_10_1007_s43188_022_00169_7
crossref_primary_10_1007_s10528_020_10023_w
crossref_primary_10_3389_fimmu_2022_1035111
crossref_primary_10_3892_mmr_2022_12795
crossref_primary_10_1080_13880209_2024_2319117
crossref_primary_10_1007_s13258_021_01103_1
crossref_primary_10_3390_cells11223642
crossref_primary_10_1186_s12890_022_01957_5
crossref_primary_10_1097_CM9_0000000000002348
crossref_primary_10_3389_fimmu_2023_1196350
crossref_primary_10_1186_s12890_021_01589_1
crossref_primary_10_3390_jcm12020604
crossref_primary_10_1007_s12010_024_05148_2
crossref_primary_10_3389_fimmu_2021_722004
crossref_primary_10_1080_21655979_2021_2000731
crossref_primary_10_1155_2022_1485033
crossref_primary_10_1038_s41420_024_02002_6
crossref_primary_10_1080_21655979_2022_2031406
crossref_primary_10_1155_2023_1257615
crossref_primary_10_1016_j_ijbiomac_2023_126951
crossref_primary_10_1155_2021_8884438
crossref_primary_10_3390_ijms25169001
crossref_primary_10_1038_s41598_024_62966_4
crossref_primary_10_1016_j_intimp_2023_111066
crossref_primary_10_3389_fcvm_2021_684348
crossref_primary_10_1155_2021_7890288
crossref_primary_10_1097_FJC_0000000000001031
crossref_primary_10_1155_2022_9923204
crossref_primary_10_1016_j_imbio_2022_152219
crossref_primary_10_1016_j_yexcr_2021_112756
crossref_primary_10_1186_s12576_023_00891_3
crossref_primary_10_1016_j_jphs_2020_11_009
crossref_primary_10_1016_j_surg_2023_06_017
crossref_primary_10_2147_JIR_S479926
crossref_primary_10_3389_fcell_2020_616416
crossref_primary_10_1016_j_amjms_2022_03_008
crossref_primary_10_1007_s13577_022_00687_4
crossref_primary_10_1177_17534259211034221
crossref_primary_10_1016_j_bbrc_2022_11_067
crossref_primary_10_1038_s41536_024_00365_z
crossref_primary_10_1007_s00430_023_00778_5
crossref_primary_10_1038_s41419_021_04117_5
crossref_primary_10_3892_etm_2024_12689
crossref_primary_10_2174_011574888X272011231128073104
crossref_primary_10_1016_j_phrs_2021_105548
crossref_primary_10_1155_2021_6878026
crossref_primary_10_1139_cjpp_2021_0255
crossref_primary_10_3724_abbs_2023090
crossref_primary_10_1080_21655979_2022_2037922
crossref_primary_10_1096_fj_202400676RR
crossref_primary_10_1186_s12950_022_00300_3
crossref_primary_10_1186_s12959_022_00413_y
crossref_primary_10_1042_BSR20201025
crossref_primary_10_1177_09603271221146790
crossref_primary_10_3389_fped_2020_573099
crossref_primary_10_3892_mmr_2020_11526
crossref_primary_10_1016_j_intimp_2025_114111
crossref_primary_10_1080_08820139_2022_2027961
crossref_primary_10_3892_etm_2024_12578
crossref_primary_10_1186_s12864_022_09073_8
crossref_primary_10_1016_j_cellsig_2025_111650
crossref_primary_10_1177_17562872231151852
crossref_primary_10_1097_MD_0000000000023444
crossref_primary_10_3390_diagnostics12061355
crossref_primary_10_1002_jcla_24985
crossref_primary_10_3389_fcimb_2021_563126
crossref_primary_10_1016_j_gene_2023_147575
crossref_primary_10_1002_ddr_21706
crossref_primary_10_1007_s11010_021_04234_x
crossref_primary_10_1177_03000605211037495
crossref_primary_10_1007_s13273_023_00341_6
crossref_primary_10_1016_j_biopha_2024_116868
crossref_primary_10_1186_s13019_024_02651_9
crossref_primary_10_1371_journal_pone_0251359
crossref_primary_10_1186_s12890_022_02091_y
crossref_primary_10_1111_odi_13590
crossref_primary_10_1007_s12013_024_01588_z
crossref_primary_10_3389_fphys_2024_1326392
crossref_primary_10_3892_etm_2022_11285
crossref_primary_10_1139_bcb_2020_0243
crossref_primary_10_1155_2021_4084371
crossref_primary_10_2174_1566524023666230710121347
crossref_primary_10_1016_j_heliyon_2023_e15034
crossref_primary_10_1080_21655979_2021_1987132
crossref_primary_10_1155_2022_7341504
crossref_primary_10_2174_1386207323666201204130031
crossref_primary_10_1097_SHK_0000000000002196
crossref_primary_10_1007_s10753_025_02240_5
crossref_primary_10_1016_j_biopha_2024_117566
crossref_primary_10_1007_s13577_022_00837_8
crossref_primary_10_1186_s12890_021_01561_z
crossref_primary_10_1002_iid3_1163
crossref_primary_10_1016_j_gendis_2021_07_004
crossref_primary_10_3389_fgene_2022_895629
Cites_doi 10.2337/db07-1795
10.1038/nature08170
10.1165/rcmb.2009-0210ST
10.1152/ajplung.00107.2016
10.1124/mol.104.005926
10.1186/cc8048
10.1164/ajrccm.163.3.2003065
10.1016/j.biopha.2018.02.129
10.1007/978-1-4939-3378-5_21
10.1001/jama.2013.281053
10.1016/j.yjmcc.2018.11.001
10.1186/1471-2164-8-166
10.1097/01.CCM.0000057841.33876.B1
10.1074/jbc.R116.760884
10.1016/j.cub.2005.02.027
10.1002/jso.23264
10.1038/379560a0
10.1016/S0002-9440(10)64570-1
10.1101/gad.1800909
10.1186/s13054-015-1091-6
10.1186/s40635-016-0096-z
10.1111/febs.13660
10.1182/blood-2009-02-204990
10.2337/db14-0298
10.1586/ers.10.78
10.1016/j.cppeds.2013.10.001
10.1002/wrna.5
10.1186/cc11144
10.7314/APJCP.2013.14.4.2311
10.1378/chest.108.5.1303
10.1186/s12943-016-0575-6
10.1089/jamp.2009.0775
10.3389/fimmu.2016.00361
10.1016/S1359-6101(03)00059-5
10.4161/rna.4.2.4640
10.1186/s13578-017-0195-x
10.1002/jcp.26274
10.1056/NEJMoa050333
10.1097/01.CCM.0000149854.61192.DC
ContentType Journal Article
Copyright COPYRIGHT 2020 BioMed Central Ltd.
2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s). 2020
Copyright_xml – notice: COPYRIGHT 2020 BioMed Central Ltd.
– notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s). 2020
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12890-020-1084-3
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
Publicly Available Content Database


MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2466
EndPage 12
ExternalDocumentID oai_doaj_org_article_33364a1206ad4244bbc0c0b1538c3f4c
PMC7036216
A616411851
32087725
10_1186_s12890_020_1084_3
Genre Journal Article
GeographicLocations China
United States--US
GeographicLocations_xml – name: China
– name: United States--US
GroupedDBID ---
0R~
23N
2WC
53G
5GY
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMB
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
UKHRP
W2D
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c626t-42d406d74b4a8781c1f5811c244991d78c07d286ffe785fedaff998e1de487c73
IEDL.DBID M48
ISSN 1471-2466
IngestDate Wed Aug 27 01:29:54 EDT 2025
Thu Aug 21 18:16:49 EDT 2025
Mon Jul 21 10:08:44 EDT 2025
Fri Jul 25 03:09:07 EDT 2025
Tue Jun 17 21:50:48 EDT 2025
Tue Jun 10 20:49:02 EDT 2025
Mon Jul 21 06:05:07 EDT 2025
Tue Jul 01 02:40:21 EDT 2025
Thu Apr 24 22:58:30 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Acute lung injury
GAB1
Sepsis
miRNA
Inflammation
TUG1
Apoptosis
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c626t-42d406d74b4a8781c1f5811c244991d78c07d286ffe785fedaff998e1de487c73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-5435-3296
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12890-020-1084-3
PMID 32087725
PQID 2379172307
PQPubID 44785
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_33364a1206ad4244bbc0c0b1538c3f4c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7036216
proquest_miscellaneous_2363049986
proquest_journals_2379172307
gale_infotracmisc_A616411851
gale_infotracacademiconefile_A616411851
pubmed_primary_32087725
crossref_citationtrail_10_1186_s12890_020_1084_3
crossref_primary_10_1186_s12890_020_1084_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-02-22
PublicationDateYYYYMMDD 2020-02-22
PublicationDate_xml – month: 02
  year: 2020
  text: 2020-02-22
  day: 22
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC pulmonary medicine
PublicationTitleAlternate BMC Pulm Med
PublicationYear 2020
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References L Li (1084_CR37) 2012; 2012
N Matsuda (1084_CR18) 2005; 67
J Xu (1084_CR24) 2017; 7
M Kawasaki (1084_CR26) 2000; 157
NW Mathy (1084_CR9) 2017; 292
Q Zhang (1084_CR13) 2013; 14
PE Parsons (1084_CR5) 2005; 33
MA Reddy (1084_CR10) 2014; 63
JE Levitt (1084_CR33) 2012; 16
SW Chi (1084_CR29) 2009; 460
TR Martin (1084_CR6) 2003; 31
GU Meduri (1084_CR4) 1995; 108
LL Chen (1084_CR7) 2010; 1
M Beitzinger (1084_CR28) 2007; 4
JE Levitt (1084_CR1) 2010; 4
1084_CR22
MD Paraskevopoulou (1084_CR35) 2016; 1402
W Xie (1084_CR39) 2018; 233
JE Wilusz (1084_CR8) 2009; 23
Y Liang (1084_CR36) 2007; 8
M Holgado-Madruga (1084_CR40) 1996; 379
RP Hebbel (1084_CR23) 2010; 115
M Sagy (1084_CR30) 2013; 43
P Toner (1084_CR31) 2015; 19
JE Sevransky (1084_CR32) 2009; 13
Y Han (1084_CR14) 2013; 107
D Jalapothu (1084_CR38) 2016; 7
ER Johnson (1084_CR3) 2010; 23
Y Kitamura (1084_CR25) 2001; 163
JH Lee (1084_CR20) 2009; 58
RB Goodman (1084_CR27) 2003; 14
S Ruiz (1084_CR19) 2016; 4
G Matute-Bello (1084_CR21) 2011; 44
Y Niu (1084_CR15) 2017; 16
H Zhang (1084_CR34) 2018; 101
K Wang (1084_CR41) 2016; 311
TL Young (1084_CR12) 2005; 15
GD Rubenfeld (1084_CR2) 2005; 353
X Zhu (1084_CR11) 2019; 126
S Su (1084_CR16) 2016; 283
1084_CR17
References_xml – volume: 58
  start-page: 344
  issue: 2
  year: 2009
  ident: 1084_CR20
  publication-title: Diabetes
  doi: 10.2337/db07-1795
– volume: 460
  start-page: 479
  issue: 7254
  year: 2009
  ident: 1084_CR29
  publication-title: Nature
  doi: 10.1038/nature08170
– volume: 44
  start-page: 725
  issue: 5
  year: 2011
  ident: 1084_CR21
  publication-title: Am J Respir Cell Mol Biol
  doi: 10.1165/rcmb.2009-0210ST
– volume: 311
  start-page: L1149
  issue: 6
  year: 2016
  ident: 1084_CR41
  publication-title: Am J Physiol Lung Cell Mol Physiol
  doi: 10.1152/ajplung.00107.2016
– volume: 67
  start-page: 1018
  issue: 4
  year: 2005
  ident: 1084_CR18
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.104.005926
– volume: 13
  start-page: R150
  issue: 5
  year: 2009
  ident: 1084_CR32
  publication-title: Crit Care (London, England)
  doi: 10.1186/cc8048
– volume: 163
  start-page: 762
  issue: 3 Pt 1
  year: 2001
  ident: 1084_CR25
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/ajrccm.163.3.2003065
– volume: 101
  start-page: 663
  year: 2018
  ident: 1084_CR34
  publication-title: Biomed Pharmacother = Biomed Pharmacother
  doi: 10.1016/j.biopha.2018.02.129
– volume: 1402
  start-page: 271
  year: 2016
  ident: 1084_CR35
  publication-title: Methods Mol Biol (Clifton, NJ)
  doi: 10.1007/978-1-4939-3378-5_21
– ident: 1084_CR22
  doi: 10.1001/jama.2013.281053
– volume: 126
  start-page: 60
  year: 2019
  ident: 1084_CR11
  publication-title: J Mol Cell Cardiol
  doi: 10.1016/j.yjmcc.2018.11.001
– volume: 8
  start-page: 166
  year: 2007
  ident: 1084_CR36
  publication-title: BMC Genomics
  doi: 10.1186/1471-2164-8-166
– volume: 31
  start-page: S184
  issue: 4 Suppl
  year: 2003
  ident: 1084_CR6
  publication-title: Crit Care Med
  doi: 10.1097/01.CCM.0000057841.33876.B1
– volume: 292
  start-page: 12375
  issue: 30
  year: 2017
  ident: 1084_CR9
  publication-title: J Biol Chem
  doi: 10.1074/jbc.R116.760884
– volume: 15
  start-page: 501
  issue: 6
  year: 2005
  ident: 1084_CR12
  publication-title: Curr Biol : CB
  doi: 10.1016/j.cub.2005.02.027
– volume: 107
  start-page: 555
  issue: 5
  year: 2013
  ident: 1084_CR14
  publication-title: J Surg Oncol
  doi: 10.1002/jso.23264
– volume: 379
  start-page: 560
  issue: 6565
  year: 1996
  ident: 1084_CR40
  publication-title: Nature
  doi: 10.1038/379560a0
– volume: 157
  start-page: 597
  issue: 2
  year: 2000
  ident: 1084_CR26
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)64570-1
– volume: 23
  start-page: 1494
  issue: 13
  year: 2009
  ident: 1084_CR8
  publication-title: Genes Dev
  doi: 10.1101/gad.1800909
– volume: 2012
  start-page: 567586
  year: 2012
  ident: 1084_CR37
  publication-title: Clin Dev Immunol
– volume: 19
  start-page: 374
  year: 2015
  ident: 1084_CR31
  publication-title: Crit Care (London, England)
  doi: 10.1186/s13054-015-1091-6
– volume: 4
  start-page: 22
  issue: 1
  year: 2016
  ident: 1084_CR19
  publication-title: Intensive Care Med Exp
  doi: 10.1186/s40635-016-0096-z
– volume: 283
  start-page: 1261
  issue: 7
  year: 2016
  ident: 1084_CR16
  publication-title: FEBS J
  doi: 10.1111/febs.13660
– volume: 115
  start-page: 2483
  issue: 12
  year: 2010
  ident: 1084_CR23
  publication-title: Blood
  doi: 10.1182/blood-2009-02-204990
– volume: 63
  start-page: 4249
  issue: 12
  year: 2014
  ident: 1084_CR10
  publication-title: Diabetes
  doi: 10.2337/db14-0298
– volume: 4
  start-page: 785
  issue: 6
  year: 2010
  ident: 1084_CR1
  publication-title: Expert Rev Respir Med
  doi: 10.1586/ers.10.78
– volume: 43
  start-page: 260
  issue: 10
  year: 2013
  ident: 1084_CR30
  publication-title: Current problems in pediatric and adolescent health care
  doi: 10.1016/j.cppeds.2013.10.001
– volume: 1
  start-page: 2
  issue: 1
  year: 2010
  ident: 1084_CR7
  publication-title: Wiley Interdiscip Rev RNA
  doi: 10.1002/wrna.5
– volume: 16
  start-page: 223
  issue: 3
  year: 2012
  ident: 1084_CR33
  publication-title: Crit Care (London, England)
  doi: 10.1186/cc11144
– volume: 14
  start-page: 2311
  issue: 4
  year: 2013
  ident: 1084_CR13
  publication-title: Asian Pac J Cancer Prev : APJCP
  doi: 10.7314/APJCP.2013.14.4.2311
– volume: 108
  start-page: 1303
  issue: 5
  year: 1995
  ident: 1084_CR4
  publication-title: Chest
  doi: 10.1378/chest.108.5.1303
– volume: 16
  start-page: 5
  issue: 1
  year: 2017
  ident: 1084_CR15
  publication-title: Mol Cancer
  doi: 10.1186/s12943-016-0575-6
– volume: 23
  start-page: 243
  issue: 4
  year: 2010
  ident: 1084_CR3
  publication-title: J Aerosol Med Pulm Drug Deliv
  doi: 10.1089/jamp.2009.0775
– volume: 7
  start-page: 361
  year: 2016
  ident: 1084_CR38
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2016.00361
– volume: 14
  start-page: 523
  issue: 6
  year: 2003
  ident: 1084_CR27
  publication-title: Cytokine Growth Factor Rev
  doi: 10.1016/S1359-6101(03)00059-5
– volume: 4
  start-page: 76
  issue: 2
  year: 2007
  ident: 1084_CR28
  publication-title: RNA Biol
  doi: 10.4161/rna.4.2.4640
– volume: 7
  start-page: 69
  year: 2017
  ident: 1084_CR24
  publication-title: Cell & bioscience
  doi: 10.1186/s13578-017-0195-x
– volume: 233
  start-page: 6615
  issue: 9
  year: 2018
  ident: 1084_CR39
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.26274
– ident: 1084_CR17
– volume: 353
  start-page: 1685
  issue: 16
  year: 2005
  ident: 1084_CR2
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa050333
– volume: 33
  start-page: 1
  issue: 1
  year: 2005
  ident: 1084_CR5
  publication-title: Crit Care Med
  doi: 10.1097/01.CCM.0000149854.61192.DC
SSID ssj0017853
Score 2.5460937
Snippet Sepsis-induced acute lung injury (ALI) is a clinical syndrome characterized by the injury of alveolar epithelium and pulmonary endothelial cells. This study...
Background Sepsis-induced acute lung injury (ALI) is a clinical syndrome characterized by the injury of alveolar epithelium and pulmonary endothelial cells....
Abstract Background Sepsis-induced acute lung injury (ALI) is a clinical syndrome characterized by the injury of alveolar epithelium and pulmonary endothelial...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 49
SubjectTerms Abdomen
Acute lung injury
Acute Lung Injury - drug therapy
Acute Lung Injury - etiology
Adaptor Proteins, Signal Transducing - drug effects
Animals
Antisense RNA
Apoptosis
Asthma
Binding sites
Causes of
Cell culture
Cell cycle
Cloning
Complications and side effects
Development and progression
Endothelium
Enzymes
Epithelium
GAB1
Genes
Genetic aspects
Health aspects
Hospitals
House mouse
Inflammation
Journalists
Laboratory animals
Lipopolysaccharides
Luciferase
Lung diseases
Male
Mice
Mice, Inbred C57BL
MicroRNA
MicroRNAs - drug effects
miRNA
Mitogens
Physiological aspects
Protein binding
Proteins
Pulmonology
Respiratory insufficiency
RNA
RNA, Long Noncoding - pharmacology
RNA, Long Noncoding - therapeutic use
Sepsis
Sepsis - complications
Taurine
TUG1
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yD-KL-G31lAiCIIRtmjTJPu6Jd4d493Dswr2F5gsrd73F7gr-98602WWLoC--NglNJjOZ-TGTXwh5j5kZl1RioU6KSd5o5poomRAqJNGoaBReFL64VOcr-eW6vj546gtrwkZ64FFwMwGjZMOrUjUBL2U550tfOjRUL5L0ePqCz9uBqZw_0OCFcg6TGzXrOebTGEIlXhqYycQLDWT9fx7JBz5pWi954IBOH5GHOXKki3HGj8m92D0h9y9ybvwpWX7t_NXlgi5XZ5ziCyk_W4wjaR_XfdszwN6wi4E2fruJ9AZsnLbdd5Aodb_oWA8OXozetldMSMfq9exsccKfkdXp5-Wnc5bfTGAeoMmGySqAiw5aOtkYbbjnqTace5AcRIJBG1_qUBmVUgQZpRialABxRR4iQBevxXNy1N118SWhMaSUxFzOYx2kkBBKSInwSZsQeO1dQcqdDK3PhOL4rsWNHYCFUXYUuwWxIw-ptKIgH_dD1iObxt86n-DG7DsiEfbwAdTDZvWw_1KPgnzAbbVorjA53-RbB7BEJL6yCwV4Ef5f84IcT3qCmflp804xbDbz3lZCA9zFWvqCvNs340gsXevi3Rb7KExlzo0qyItRj_ZLEhXyMVZ1QfREwyZrnrZ07beBBByJ0yquXv0PIb0mDyq0DbypXx2To82PbXwDsdbGvR3M6jcIICGv
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgifls9JYIgCGGbJk2zT7In3h3i3cOxC_sWmi9v5eyu113B_96ZNluvCPfapDSZzGTy60x-Q8h7jMzYqCLzZVRM8rpitg6SCaF8FLUKWuFF4bNzdbqQX5flMv1wa1Na5X5P7DZqv3b4j3xSiAqQBaYtf9r8Ylg1CqOrqYTGXXIPqcswpataDoALC8-LFMnkWk1ajlE1hoCJ5xrGM_JFHWX__xvzDc80zpq84YaOH5GH6fxIZ_2CPyZ3QvOE3D9LEfKnZP6tcRfnMzpfnHCKdVJ-r_A0SduwaVctAwQOa-lp7XbbQK_A0umq-QFypfYP7bPCwZfRn6sLJqRl5WZyMjviz8ji-Mv88ylLlROYA4CyZbLw4Kh9Ja2sdaW547HUnDvw5XAe9JV2eeULrWIMIKMYfB0j4K7AfQAA4yrxnBw06ya8JDT4GKOYymkovRQSDhRSIoiqtPe8dDYj-V6GxiVacaxucWU6eKGV6cVuQOzIRiqNyMjH4ZVNz6lxW-cjXJihI9Jhdw_W199Nsi4jQLVkzYtc1R5v7lnrcpdb3M2diNJl5AMuq0GjhcG5Ot09gCki_ZWZKUCN8P2SZ-Rw1BOMzY2b94phkrG35p9qZuTd0IxvYgJbE9Y77KMwoDnVKiMvej0apiQKZGUsyoxUIw0bzXnc0qwuOypwpE8ruHp1-7BekwcFaj3exC8OycH2ehfewFlqa992BvMX0_QZvA
  priority: 102
  providerName: ProQuest
Title LncRNA TUG1 alleviates sepsis-induced acute lung injury by targeting miR-34b-5p/GAB1
URI https://www.ncbi.nlm.nih.gov/pubmed/32087725
https://www.proquest.com/docview/2379172307
https://www.proquest.com/docview/2363049986
https://pubmed.ncbi.nlm.nih.gov/PMC7036216
https://doaj.org/article/33364a1206ad4244bbc0c0b1538c3f4c
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zi9swEB72gGVfSu-63QYXCoWCu5YlS85DKUnZg9KEEhLIm7B1bFNSJ81Ruv--M46TxnTpQ18tCVuaGc18HukbgNeUmSm89JFNvYwEy1VU5E5EnEvreS5dJumicK8vr0fi0zgdH8C2vFW9gMs7oR3Vkxotpu9-_bj9gAb_vjL4TJ4vGWXLIgJCLM7wPYdwjI5JkZ32xJ-kgkLXVCc27xx2Cic8IYI8qpu956UqMv-_t-w9n9U8T7nnoC7vw706sgw7G1V4AAeufAgnvTp3_giGn0sz6HfC4eiKhVRB5eeE4sxw6ebLyTJCbI5StmFu1isXTnEPCCflN1zxsLgNN-fF0cuF3yeDiIsiSufnV50uewyjy4vhx-uorqkQGYQuq0gkFl24VaIQeaYyZphPM8YMenmMFK3KTKxskknvHS6Xdzb3HhGZY9YhtDGKP4Gjcla6ZxA6673nbdF2qRVcYKghBMErlVnLUlMEEG_XUJuacJzqXkx1BTwyqTcS0CgB4ikVmgfwdjdkvmHb-FfnLglm15GIsqsHs8WNru1Oc1Q6kbMklrmlO31FYWITF7TPG-6FCeANiVWTguHHmby-lYBTJGIs3ZGIJ_H9KQvgrNETzdA0m7eKobdarBOuEA7TWfsAXu2aaSQdbSvdbE19JKU625kM4OlGj3ZT2qpjAKqhYY05N1vKydeKJJyI1RImn__3yBdwmpBt0PX95AyOVou1e4kB2KpowaEaqxYcdy_6Xwat6jdGqzK132huLXA
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJwEviG8CA4wEQkKyGseO4z4g1MK2jrUVqlppb1niDygaaVla0P4p_kbumrQsQtrbXmO7ic_39eud7wh5jZGZ3CvPbOwVkzxLWJ45yYRQ1otMOa3wovBwpPpT-fkkPtkhfzZ3YTCtcqMT14razg3-R96ORALIAtOWPyx-MuwahdHVTQuNii2O3cVvgGzl-6NPcL5vouhgf_Kxz-quAsyA875kMrJgxGwic5npRHPDfaw5N2DnwFeyiTZhYiOtvHeJjr2zmfeASRy3Dpx7kwj43RtkVwqAMi2y29sffRlv4xawQtSxU65Vu-QYx2MI0XiogQIN67duEvC_KbhkC5t5mpcM38Fdcqf2WGm3YrF7ZMcV98nNYR2Tf0Amg8KMR106mR5yip1Zfs3Qf6WlW5SzkgHmB-6xNDOrpaNnoFvorPgOJ0nzC1rloYP1pD9mYyZkzuJF-7Db4w_J9Fqo-oi0innhnhDqrPdedGTHxVYKCS6MlAjbEm0tj00ekHBDw9TUhcyxn8ZZugY0WqUV2VMgO9Y_lakIyLvtkkVVxeOqyT08mO1ELMC9fjA__5rW8pwKYGaZ8ShUmcW7gnluQhPmaD-M8NIE5C0ea4pqAj7OZPVtB9giFtxKuwpwKrw_5gHZa8wE8TbN4Q1jpLV6KdN_whCQV9thXIkpc4Wbr3COwhBqR6uAPK74aLslEWEdyCgOSNLgsMaemyPF7Nu6-DgWbIu4enr1Z70kt_qT4SAdHI2On5HbEUoA1gGI9khreb5yz8GTW-YvavGh5PS6JfYvUUdXwQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=LncRNA+TUG1+alleviates+sepsis-induced+acute+lung+injury+by+targeting+miR-34b-5p%2FGAB1&rft.jtitle=BMC+pulmonary+medicine&rft.au=Qiu%2C+Nan&rft.au=Xu%2C+Xinmei&rft.au=He%2C+Yingying&rft.date=2020-02-22&rft.pub=BioMed+Central&rft.eissn=1471-2466&rft.volume=20&rft_id=info:doi/10.1186%2Fs12890-020-1084-3&rft_id=info%3Apmid%2F32087725&rft.externalDocID=PMC7036216
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2466&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2466&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2466&client=summon